A multifactorial prognostic model for adult soft tissue sarcoma considering clinical, histopathological and molecular data

Anticancer Research

Volumn 20, Issue 3 B, 2000, Pages 2065-2072

  Würl, Peter ^b   Lautenschläger, Christine ^a   Meye, Axel ^a   Schmidt, Hannelore ^a   Bache, Matthias ^a   Rath, Friedrich Wilhelm ^a   Schönfelder, Manfred ^b   Taubert, Helge ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Martin Luther Univ Halle Wittenberg ^*

Author keywords

Mdm2; Multifactorial model; p53; Prognosis; Soft tissue sarcoma

Indexed keywords

TUMOR MARKER;

ADULT; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MESENCHYME; MOLECULAR BIOLOGY; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SOFT TISSUE SARCOMA;

ABDOMINAL NEOPLASMS; ADULT; AGE FACTORS; COHORT STUDIES; EXTREMITIES; HUMANS; LIFE TABLES; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REGRESSION ANALYSIS; RETROPERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; RISK; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0342646995     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Enzinger FM and Weiss SW: Soft Tissue Tumors. Third edition, St. Louis Missouri, Mosby, 1995.
2. Coindre JM, Trojani M and Contesso G et al: Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer 58: 306-309, 1986.
3. Guillou L, Coindre JM and Bonichon F et al: Comparative study of National Cancer Institute and French Federation of Cancer Centers' Sarcoma Group Grading Systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 15: 350-362, 1997.
4. Suit HD, Mankin HJ and Wood WC et al: Treatment of the patient stage MO soft tissue sarcoma. J Clin Oncol 6: 854, 1988.
5. Singer S, Corson JM, Demetri GD et al: Prognostic factors predictive of survival for truncal and retroperitoneal soft tissue sarcoma. Ann Surg 221: 185-195, 1995.
6. Coindre JM, Terrier P and Bui NB et al: Prognostic factors in adult patients with locally controlled soft tissue sarcoma: a study of 546 patients from the French federation of cancer centers sarcoma group. J Clin Oncol 14: 869-877, 1996.
7. Tsujimoto M, Aozasa K, Ueda T, Morimura Y, Komatsubara Y and Doi T: Multivariate analysis for histologic prognostic factors in soft tissue sarcomas. Cancer 62: 994-998, 1998.
8. Brennan MF, Casper ES, Harrison LB, Shiu MH, Gaynor J and Hajdu SI: The role of multimodality therapy in soft-tissue sarcoma. Ann Surg 214: 328-338, 1991.
9. Markhede G, Angervall L and Stener B: A multivariate analysis of the prognosis after surgical treatment of malignant soft tissue tumors. Cancer 49: 1721-1733, 1982.
10. Singer S, Corson JM, Gonin R, Labow B and Eberlein TJ: Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg 219: 165-173, 1994.
11. Lewis JJ, Leung D, Heslin M, Woodruff JM and Brennan MF Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. J Clin Oncol 15: 646-652, 1997.
12. Willert CG, Schiller AL, Suit HD, Mankin HJ and Rosenberg A: The histologic response of soft tissue sarcoma to radiation therapy. Cancer 60: 1500-1504, 1987.
13. Stinson SF, DeLaney TF and Greenberg J et al: Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcoma. Int J Radiat Oncol Biol Phys 21: 1493-1499, 1991.
14. Patel SP, Vodhan Raj S and Papadopoulos N et al: High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies - dose response and schedule dependence. J Clin Oncol 15: 2378-2384, 1997.
15. Casper ES, Schwartz GK, Sugarman A, Leung D and Brennan MF: Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma. J Clin Oncol 15: 2111-2117, 1997,
16. Tomita Y, Aozasa K and Myoui A et al: Histologic grading for soft tissue sarcomas. An analysis of 194 cases including AgNOR count and mast-cell count. Int J Cancer 54: 194-199, 1993.
17. Nakanishi H, Ohsawa M, Naka N, Uchida A, Ochi T and Aozasa K: Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: their correlation with prognosis. Oncology 54: 238-244, 1997.
18. Cordon-Cardo C, Wartinger D, Patrylak D et al: Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer. J Natl Cancer Inst 84: 1251-1256, 1992.
19. Wang J, Coltera MD and Gown AM: Abnormalities of p53 and p11 ORb tumor suppressor gene expression in human soft tissue tumors: correlation with cell proliferation and tumor grade. Mod Pathol 8: 837-842, 1995.
20. Dei Tos AP, Maestro R and Doglioni C et al: Tumor suppressor genes and related molecules in leiomyosarcoma. Am J Pathol 148: 1037-1045, 1996.
21. Harris CC: p53 tumor suppressor gene: from the basic research laboratory to the clinican abridged historical perspective. Carcinogenesis 17: 1187-1198, 1996.
22. Gottlieb MG and Oren M: p53 in growth control and neoplasia. Bioch Biophys Acta 1287: 77-102, 1996.
23. Home GM, Anderson JJ and Tiniakos DG et al: p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 73: 29-35, 1996.
24. Hainaut P, Hernandez T and Robinson A et al: IARC database of p53 mutations in human tumors and cell lines: update compilation, revised formats and new visualisation tools. Nucl Acids Res 26: 205-213, 1998.
25. Cordon-Cardo C, Latres E and Drobnjak M et al: Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54: 794-799, 1994.
26. Kondo S, Barnett GH and Hara H et al: MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 10: 2001-2006, 1995.
27. Kondo S, Hara H, Kaakaji R, Fukuda T and Tsuneyoshi M: Mdm2 gene mediates the expression of mdr1 gene and p-glycoprotein in a human glioblastoma cell line. Br J Cancer 74: 1263-1268, 1996.
28. Hirakawa N, Naka T and Yamamoto I: Overexpression of bcl-2 protein in synovial sarcoma: a comparative study of other soft tissue spindle cell sarcomas and an additional analysis by fluorescence in situ hybridization. Hum Pathol 27: 1060-1065, 1996.
29. Pilotti S, Mezzelani A, Azzarelli A, Rilke F and Pierotti MA: Bcl-2 expression in synovial sarcoma. J Pathol 184: 337-340, 1998.
30. Stein U, Wunderlich V, Haensch W and Schmidt-Peter P: Expression of the mdr1 gene in bone and soft tissue sarcomas of adult patients. Eur J Cancer 29A: 1979-1981, 1993.
31. Jaffrezou J-P, Chen G, Duran GE, Kuhl JS and Sikic BI: Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis. J Natl Cancer Inst 86: 1152-1158, 1994.
32. Brennan MF: The surgeon as leader in cancer care: lessons learned from the study of soft tissue sarcoma. J Am Col Surg 182: 520-529, 1996.
33. Würl P, Taubert H and Meye A et al: Prognostic value of immunohistochemistry for p53 in primary soft tissue sarcomas: a multivariate analysis of five antibodies. J Cancer Res Clin Oncol 123: 502-508, 1997.
34. Wurl P, Meye M and Berger D et al: Prognostic relevance of C-terminal MDM2 detection is enhanced by p53 positivity in soft tissue sarcoma. Diagn Mol Pathol 6: 249-254, 1997.
35. Van Unnik JAM, Coindre JM and Albus-Lutter CE et al: Grading of Soft Tissue Sarcoma: Experience of the EORTC Soft and Bone Sarcoma Group. Eur J Cancer 29A: 2089-2093, 1998.
36. Taubert H, Wurl P and Meye A et al: Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma. Cancer 76: 1187-1196, 1995.
37. Wurl P, Taubert H and Bache M et al: Frequent occurrence of p53 mutations in rhabdo- and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. Int J Cancer 69: 317-323, 1996.
38. Cox DR and Oakes D: Analysis of survival data. Chapman and Hall, New York 1984, 201.
39. nd ed., 624.
40. Kleinbaum DG: Survival analysis: a self-learning text. Springer Verlag, New York 1996, 324.
41. Coindre JM, Pathology and grading of soft tissue tumors. In: Multidisciplinary treatment of soft tissue sarcomas. 2. Soft tissue neoplasms-therapy. Kluwer Academic Publishers Norwell (Massachusetts), 1993, 1-22.
42. Karakousis CP, Proimakls C, Roa U and Velez AF: Local recurrence and survival in soft tissue sarcoma. Ann Surg Oncol 3: 255-260, 1996.
43. Hashimoto H, Daimaru Y, Takeshita S, Tsuneyoshl M and Enjoji M: Prognostic significance of histologic parameters of soft tissue sarcomas. Cancer 70: 2816-2822, 1992.
44. Heslin MJ, Lewis JJ and Nadler E et al: Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. J Clin Oncol 15: 2832-2839, 1997.
45. Peiper M, Zurakowski D and Zornig C: Survival in primary soft tissue sarcoma of the extremities and trunk. Langenhecks Arch Chir 382: 203-208, 1997.
46. Jensen OM, Hogh J, Ostgaard SE, Nordentoft AM and Sneppen O: Histopathological grading of soft tissue tumours: Prognostic significance in a prospective study of 278 consecutive cases. J Pathol 163: 19-24, 1991.
47. Peabody TD, Monson D, Montag A, Schell MJ, Finn H and Simon MA: A comparison of the prognoses for deep and subcutaneous sarcomas of the extremities. J Bone Joint Surg 76A: 1167-1173, 1994.
48. Nakanishi H, Tomita Y and Ohsawa M et al: Tumor size as a prognostic indicator of histologic grade of soft tissue sarcoma. J Surg Oncol 6: 183-187, 1997.
49. Gaynor JJ, Tan CC and Casper ES et al: Refinement of clinicopathologic staging for soft - tissue sarcoma of the extremity a study of 423 adults. J Clin Oncol 10: 1317-1329, 1992.
50. Pisters PWT, Leung DHY, Woodruff J, Shi W and Brennan MF: Analysis of prognostic fadors in 1,041 patients with local soft tissue sarcoma of the extremity J Clin Oncol 14: 1679-1689, 1996.
51. Casson AG, Putnam JP and Natarajan G et al: Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma. Cancer 69: 662-668, 1992.
52. Choong PFM, Pritchard DJ, Rock MG, Sim FH and Frassic FJ: Survival after pulmonary metastasectomy in soft tissue sarcoma. Acta Orthop Scand 66: 561-568, 1995.
53. Fong Y, Coit DG, Woodruff JM and Brennan MF: Lymph node metastasis from soft tissue sarcoma in adults: analysis of data from a prospective database of 1,772 sarcoma patients. Ann Surg 217: 72-77, 1993.
54. Brennan MF: Chirurgische Therapie und Prognose des Weichteilsarkoms. Chirurg 64: 449-454, 1992.
55. Dijkstra MD, Balm AJM and Coevorden FV et al: Survival of adult patients with head and neck soft tissue sarcomas. Clin Otolaryngol 21: 66-71, 1996.
56. Yang RS, Lane JM and Eilber FR et al: High grade soft tissue sarcoma of the flexor fossae. Cancer 76: 1398-1405, 1995.
57. Saenz NC, Ghavimi F, Gerald W, Gollamudi S and LaQuaglia MP: Chest wall rhabdomyosarcoma. Cancer 80: 1513-1517, 1997.
58. Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997.
59. Kubbutat MHG, Jones SN and Vousden KH: Regulation of p53 stability by Mdm2. Nature 387: 299-303, 1997.
60. Oliner JD, Pietenpol JA and Thiagalingam S et al: Oncoprotein mdm2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860, 1993.
61. Wu X, Bayle H, Olson D and Levine AJ: The p53-mdm2 autoregularory feedback loop. Genes Dev 7: 1126-1132, 1993.
62. Latres E, Drobnjak M and Pollack D et al: Chromosome 17 abnormalities and p53 mutation in adult soft tissue sarcomas. Am J Pathol 145: 345-354, 1994.
63. Yoo J, Lee HK, Kang CS, Park WS, Lee JY and Shim SI: p53 gene mutations and p53 protein expression in human soft tissue sarcomas. Arch Pathol Lab Med 121: 395-399, 1997.